QuantLogix ← CVS scorecard
📅 CVS Earnings Preview
CVS HEALTH CORPORATION
Next report (est.)
September 19, 2026
Countdown
98 days
EPS growth YoY
+3185.7%
Revenue growth YoY
+5.2%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
May 6, 2026 ±2.3% +7.7% under-priced
October 29, 2025 ±1.9% -1.9% under-priced
July 31, 2025 ±4.0% -0.3% over-priced
May 1, 2025 ±2.0% +4.1% under-priced
November 6, 2024 ±2.4% +11.3% under-priced
August 7, 2024 ±3.9% -3.2% over-priced
May 1, 2024 ±1.4% -16.8% under-priced
November 1, 2023 ±2.1% -0.4% over-priced
Across these reports, options implied an average ±2.5% move vs an actual average of 5.7% — the stock stayed inside the implied band 38% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q1 FY2026 $2.30 $100.4B $3.0B
Q3 FY2025 $-3.13 $102.9B $-4.0B
Q2 FY2025 $0.80 $98.9B $1.0B
Q1 FY2025 $1.41 $94.6B $1.8B
Analyst posture
Buy / Strong Buy
27
Hold
6
Sell
0
Stable: +1 net change 30d
Live 5-factor engine read: Strong Buy · 70/100 Full scorecard →
Get alerted before every CVS report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on CVS before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

CVS HEALTH CORPORATION (CVS) reports in 98 days, with the next report estimated for September 19, 2026. Across the last 8 reports, options priced an average ±2.5% earnings move while the stock actually moved 5.7% on average — the market has been roughly fair on CVS's earnings risk. Fundamentals into the print: EPS up 3185.7% year-over-year, revenue up 5.2%. QuantLogix's live 5-factor engine currently reads CVS as a strong buy at 70/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →